April 30, 2021
Inducible suppressive T-cell JB-101, which we are developing with Juntendo University, has been designated as an item subject to the Ministry of Health, Labour and Welfare’s “Pioneer Review Designation System”.
JUNTEN BIO Co., Ltd. was established as Juntendo University’s venture company on the basis of Juntendo University’s research seeds.
Our aim is to develop a novel type of cell therapy in Japan and thus to contribute to the global healthcare industry.
With Juntendo University’s research seeds as the basis, we have studied the mechanism of immune rejection within the body, resulting in successful preparation of inducible inhibitory
T-cells.
Our aim is to achieve the induction of immune tolerance (and the discontinuation of immunosuppressant administration) with a new treatment using these inducible inhibitory
T-cells.
At the present time, clinical studies are being performed on cell therapy for specific inhibition of immunity associated with living-donor liver transplants, using inducible inhibitory T-cells.
・Development of cellular medicines for cell therapy for
living-donor liver transplants, late living-donor liver transplants
(i.e. a considerable time after transplantation),
and brain-dead liver transplants.
・Development of cell therapy and antibody drugs for living-donor kidney transplants.
April 30, 2021
Inducible suppressive T-cell JB-101, which we are developing with Juntendo University, has been designated as an item subject to the Ministry of Health, Labour and Welfare’s “Pioneer Review Designation System”.
September 4, 2020
An investigator-initiated clinical study was started with collaborative researchers at Juntendo University.
